#NEWS: There is an urgent need for additional targeted therapies for people living with hard-to-treat cancers, which are associated with a poor prognosis. We are pleased to announce that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to our HER2 mutation targeting investigational treatment for certain hard-to-treat types of lung cancer. This designation is given to medicines for rare diseases, promoting quicker development and streamlined approval to ensure new medicines can get to patients as quickly as possible. Learn more about our commitment to lung cancer: https://lnkd.in/eJksrN99
This is great news for all affected patients👍🏻
Thank you for sharing Ana. Very hopeful decision indeed!
Excellent
Lead Scheduling Manager and Project Controls Specialist at Siemens Energy Transmission Solutions
2dExcellent news to develop further the treatment and to continue on this difficult path to bring heslth benefits to the onne that need it most. Wishing you lots of success ,